Cunniff Lab

The Cunniff lab is interested in how mitochondrial dynamics influence cell processes and is identifying new therapeutics targets for aggressive cancers.

[Cunniff Lab @CunniffLab]

Congratulations to Dr. Nate Shannon on his recently published manuscript! Lots of exciting findings to follow up on related to Miro1 and mitochondrial positioning. https://t.co/IbLRe7J4go

[Cunniff Lab @CunniffLab]

@LabFriedman @CurrentBiology @madeleinemarlar Excellent work!

[Cunniff Lab @CunniffLab]

@roybiolab Congrats!

[Cunniff Lab @CunniffLab]

Congrats to Nate on an excellent thesis!

[The Robert Larner, M.D. College of Medicine @UVMLarnerMed]

Congrats Nathaniel Shannon, #UVMLarnerMed CMB graduate Ph.D. candidate, who successfully defended his dissertation, “The Role Of Miro1 Mediated Mitochondrial Positioning On Redox...” Pictured (left) w/ advisor @BrianCunniff, Ph.D.
@CunniffLab
@UVMResearch
@uvmcmb
@UVMGradCollege

[Cunniff Lab @CunniffLab]

Come check out PhD candidate Victoria Gibson discuss the importance of Peroxiredoxin 3 in mesothelioma tumors at #SfRBM2024. SYMPOSIA SESSION 3: Unveiling the Therapeutic Potential: Exploring Redox Signaling from Fundamentals to Drug Targets 2:45pm @RedoxVT @RSOncologyLLC @SFRBM

[Cunniff Lab @CunniffLab]

PhD Candidate Nate Shannon's first author paper out as a pre-print. Very proud of Nate! Some very interesting DEGs dependent on Miro1 expression and an interesting and evolving cell cycle/ERK1/2 story! @UVMcancercenter @RedoxVT #mitochondria
https://t.co/aGTgTcdMfN

[Cunniff Lab @CunniffLab]

@KFW_Lab @wakeforestmed @WakeCancer Congrats- great team down there!

[Cunniff Lab @CunniffLab]

@echouchani @HHMINEWS @DanaFarber @HarvardCellBio Congrats, Ed. Well deserved!

[The Robert Larner, M.D. College of Medicine @UVMLarnerMed]

News from @UVMcancercenter and @RedoxVT, the Redox Biology and Pathology Program at #UVMLarnerMed.

[Cunniff Lab @CunniffLab]

Come chat at the booth, we have warm cookies!

[RS Oncology @RSOncologyLLC]

Meet us today June 2nd to hear Brian Cunniff, our CSO, talk about #mitochondrial dysfunction in cancer and how PRX3 plays a role. Booth #23094 #ASCO24 #cancerresearch @CunniffLab

[Cunniff Lab @CunniffLab]

Excited to see Dean present exciting data around the Phase 1 trial of RSO-021 at #ASCO24. A redox-dependent cancer therapy currently being tested in Phase 2! @RedoxVT @UVMcancercenter @dean_fennell @RSOncologyLLC https://t.co/g0VCHRWvGl

[RS Oncology @RSOncologyLLC]

#ASCO24 Abstracts have been published! See the short list of rapid oral abstracts in Developmental Therapeutics - Molecularly Targeted Agents & Tumor Biology and you will see our first-in-human phase 1 for RSO-021 @dean_fennell @CunniffLab @PRCLeicester
https://t.co/4MkeTGXoSi

[Cunniff Lab @CunniffLab]

Much deserved @dean_fennell !

[Liz Darlison MBE DL @darloliz]

Congratulations @dean_fennell, very much deserved. You lead a great team, it’s a privilege to be part of it and a pleasure working alongside you.

https://t.co/jo0oY3u8Qm

[Cunniff Lab @CunniffLab]

Congrats to @RSOncologyLLC for this much deserved recognition at #ASCO24 . Looking forward to @dean_fennell giving and exciting talk! @RedoxVT

[RS Oncology @RSOncologyLLC]

RSO-021 novel therapy and first-in-human clinical trial outcomes🫁will be presented on June 3rd at #ASCO24 with @dean_fennell #CancerResearch @BrianCunniff @UVMcancercenter
https://t.co/PeuyWyr8F5

[Cunniff Lab @CunniffLab]

Always an excellent meeting with great science and clinical progress being showcased! @RedoxVT @UVMcancercenter @RSOncologyLLC

[RS Oncology @RSOncologyLLC]

Sharing our 🔬scientific findings and preclinical data🫁. If you are at #AACR24 #SanDiego stop by today to see our presentation ~ @9am_today Titled: First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in #meso. #taketwo

[Cunniff Lab @CunniffLab]

@RedoxVT @UVMcancercenter

[RS Oncology @RSOncologyLLC]

Presenting two posters with new discoveries 🔬and potential biomarkers associated with RSO-021 anticancer activity @AACR San Diego, April 7th and April 9th. George Naumov will be there along with Brian Cunniff @CunniffLab, will you? #biotech #CancerResearch

[Cunniff Lab @CunniffLab]

Looking forward to presenting our new data in support of the anti-cancer activity of RSO-021, lots of fresh discoveries! @RedoxVT @dean_fennell @UVMcancercenter

[RS Oncology @RSOncologyLLC]

Gearing up for #SanDiego next month. But you won't find us on the beach April 7th or 9th, since we will be presenting our posters at @AACR 2024. Add us to your itinerary to see our 🐭preclinical anticancer activity #Mesothelioma #CancerResearch @BrianCunniff @dean_fennell

[Cunniff Lab @CunniffLab]

@MarceloBonini8 Congrats, Marcelo!

[RS Oncology @RSOncologyLLC]

Happy to announce our abstract has been approved 👏👏 #BTOG24 Our CSO Brian Cunniff, Phd, @CunniffLab will be presenting "First-in-class peroxiredoxin 3 (PRX3) inhibitors" poster. Stop by the welcome reception Wednesday April 17th, 18:30 – 20:00, say hello or ask questions.

[NilsBurger @burger_nils]

Happy to share our review with @echouchani on recent advances in cysteine proteomics! @HarvardCellBio @DFCI_CancerBio
https://t.co/yqm2tqi16d